Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

INTRODUCTION: The mineralocorticoid receptor (MR) blocker esaxerenone is a new treatment for hypertension in Japan and under development for treatment of diabetic nephropathy. Hepatic impairment is known to impact the pharmacokinetics (PKs) of other MR blocking drugs. The aim of the present study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurata, Akifumi, Yoshida, Takafumi, Inoue, Megumi, Ishizuka, Tomoko, Nakatsu, Takafumi, Shimizu, Takako, Kato, Manabu, Nishikawa, Yasuhiro, Ishizuka, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979450/
https://www.ncbi.nlm.nih.gov/pubmed/31705436
http://dx.doi.org/10.1007/s12325-019-01121-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979450/
https://www.ncbi.nlm.nih.gov/pubmed/31705436
http://dx.doi.org/10.1007/s12325-019-01121-2

Ejemplares similares